XML 30 R20.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Note 12 - Segment Information | 9 Months Ended
--- | ---
Dec. 31, 2023
Notes to Financial Statements |
Segment Reporting Disclosure [Text Block] | Note 12. S egment Information The following tables set forth our segment information:
|  | Three Months Ended December 31, |  |  | Nine Months Ended December 31, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sterilization and Disinfection Control |  | $ | 19,338 |  |  | $ | 16,283 |  |  | $ | 52,345 |  |  | $ | 48,021 |
Clinical Genomics |  |  | 12,546 |  |  |  | 15,585 |  |  |  | 41,464 |  |  |  | 48,525 |
Biopharmaceutical Development |  |  | 9,430 |  |  |  | 11,646 |  |  |  | 28,526 |  |  |  | 34,757 |
Calibration Solutions |  |  | 12,159 |  |  |  | 10,773 |  |  |  | 34,948 |  |  |  | 32,186 |
Total revenues (a) |  | $ | 53,473 |  |  | $ | 54,287 |  |  | $ | 157,283 |  |  | $ | 163,489 |
Gross profit: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sterilization and Disinfection Control |  | $ | 13,951 |  |  | $ | 11,614 |  |  | $ | 38,018 |  |  | $ | 34,581 |
Clinical Genomics |  |  | 6,449 |  |  |  | 8,045 |  |  |  | 20,904 |  |  |  | 26,535 |
Biopharmaceutical Development |  |  | 5,841 |  |  |  | 7,359 |  |  |  | 17,783 |  |  |  | 21,993 |
Calibration Solutions |  |  | 7,212 |  |  |  | 5,740 |  |  |  | 20,050 |  |  |  | 17,411 |
Reportable segment gross profit |  |  | 33,453 |  |  |  | 32,758 |  |  |  | 96,755 |  |  |  | 100,520 |
Corporate and Other (b) |  |  | (51 | ) |  |  | 7 |  |  |  | (61 | ) |  |  | (28 | )
Gross profit |  | $ | 33,402 |  |  | $ | 32,765 |  |  | $ | 96,694 |  |  | $ | 100,492 |
Reconciling Items: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating expense |  |  | 33,469 |  |  |  | 29,363 |  |  |  | 97,485 |  |  |  | 97,689 |
Operating (loss) income |  |  | (67 | ) |  |  | 3,402 |  |  |  | (791 | ) |  |  | 2,803 |
Nonoperating (income) expense, net |  |  | (2,013 | ) |  |  | 1,486 |  |  |  | (475 | ) |  |  | 2,915 |
Earnings (loss) before income taxes |  | $ | 1,946 |  |  | $ | 1,916 |  |  | $ | (316 | ) |  | $ | (112 | )
| (a) | Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
| (b) | Unallocated corporate expenses are reported within Corporate and Other.
The following table sets forth inventories by reportable segment. Our chief operating decision maker is not provided with any other segment asset information.
|  | December 31, |  |  | March 31, |
|  | 2023 |  |  | 2023 |
Sterilization and Disinfection Control |  | $ | 7,593 |  |  | $ | 3,492 |
Clinical Genomics |  |  | 11,529 |  |  |  | 13,985 |
Biopharmaceutical Development |  |  | 8,183 |  |  |  | 8,384 |
Calibration Solutions |  |  | 8,668 |  |  |  | 8,781 |
Total inventories |  | $ | 35,973 |  |  | $ | 34,642 |
Inventories from GKE total $4,077 as of December 31, 2023, net of $412 fair value amortization step-up recorded during the three months ended December 31, 2023. GKE inventories are included in our Sterilization and Disinfection Control division.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//280/tableOfContent Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration